HOLDco

The 2019 JPMorgan Healthcare Conference opened with nearly $82 billion in deals announced in the first week alone. This episode unpacks the mega-mergers, FDA moves, and why the ACA was the loudest silence in the room.

Show Notes

The 37th Annual J.P. Morgan Healthcare Conference arrived in January 2019 with an unusually loud bang — two blockbuster acquisitions announced before the conference even opened its doors. This episode of HoldCo draws on the full JPM Healthcare deal and conference analysis to break down what the event revealed about where healthcare M&A, regulatory policy, and care delivery were all heading at the start of that year.
Here's what the episode covers:
  • Bristol-Myers Squibb's $74B Celgene acquisition — announced January 3rd, it instantly ranked among the largest healthcare deals in history and signaled that big pharma was playing offense in 2019.
  • Eli Lilly's $8B move on Loxo Oncology — a 68% premium bet on precision oncology science targeting oncogenic drivers, notable even in a week dominated by a far larger deal.
  • FDA Commissioner Scott Gottlieb's agenda — a new office to streamline drug review and a push for generic drug competition, both framed as structural solutions to the drug-pricing problem.
  • CVS Health's post-Aetna vision — CEO Larry Merlo outlined a pivot toward "health hub" concept stores and data-driven pharmacy staff, making the case that the Aetna integration was a long-term care delivery play, not just a financial one.
  • Sage Therapeutics' 43% single-day stock jump — postpartum depression data that surprised the conference floor and illustrated just how much investor appetite existed for breakthroughs in underfunded therapeutic areas.
  • The ACA's conspicuous absence — after years as a dominant conference theme, the Affordable Care Act was barely discussed in 2019, reflecting a sector-wide decision to stop waiting on Washington and drive consolidation from within.
The episode also examines the revenue cycle management trends spotlighted by Intermountain Healthcare and Mercy Health — including Ensemble Health Partners' nine-fold EBITDA growth in two years — and puts the macro M&A picture in context: a Capital One survey found 44% of respondents named M&A as their top growth strategy heading into 2019, with loan-backed healthcare deals totaling $32.2 billion in 2018 alone. For more from the show, check out the episode Your AI Acquisition Just Inherited 20,000 GDPR Violations, which explores the hidden compliance risks that surface when deals close fast.
Investment Bank

What is HOLDco?

An operator-led view of holding company work: acquiring, building and running durable, cash-producing businesses in the real economy. Deal criteria, diligence, integration, capital allocation, and the management questions that arrive the day after a close.

Each episode takes one decision — what to pay, what to fix first, when to keep the seller and when not to, how to fund the next deal — and reasons it through from an operator's chair rather than a spreadsheet. Written for people buying and running businesses, not spectating on them. Five or six minutes an episode.

Topics include deal criteria and screening, diligence that finds the real risk, deal structure and seller financing, integration priorities after close, capital allocation, management transitions, and running several businesses at once.

Produced by HOLD.co, an operator-led holding company. Full details, services and further reading at https://hold.co